How This Sleeper Biotech, With A 687% Gain, Is Making A Comeback
Is shrugging off several messy years in gene therapy development, an analyst said Thursday as he initiated coverage of the biotech stock with an outperform…
Source: biztoc.com
📰 Solid Bio News
Solid Bio News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Solid Bio. Real-time updates on events, politics, business and more.
Pfizer: New Potential Billion-Dollar Drugs Under Development (NYSE:PFE)
Pfizer has a pipeline with more than 90 drugs in development. Pfizer is developing two drugs capable of generating more than a billion sales. Competition is fierce but Pfizer is in the race.
United States Sarepta Exondys Centers For Disease Screen Showing Virus Analysis Software User Interface Antibiotics In Laboratory Research Scientist
Source: seekingalpha.com
Moving Forward after Two Deaths in a Gene Therapy Trial of Myotubular Myopathy
Moving Forward after Two Deaths in a Gene Therapy Trial of Myotubular Myopathy 1 The sponsor of this clinical study, Audentes Therapeutics (which was acquired by Japan’s Astellas Pharma in 2019), had generated impressive efficacy studies in a canine model of MTM 2 and conducted non-primate (NHP) safety studies before advancing into the clinic. 3 The initial cohort of six pediatric MTM patients dosed at 1×10 14 genome copies (GC)/kg also showed encouraging results. However, all three patien...
United States Astellas Pharma Jesse Gelsinger American Society For Gene Dose Intravenous Administration Disease Community
Source: genengnews.com